A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Dose of Intravenous CS 1103 Following a Single Intravenous Dose of Fentanyl in Healthy Subjects With Naloxone Blockade
Latest Information Update: 15 May 2026
At a glance
- Drugs CS 1103 (Primary) ; Fentanyl (Primary) ; Naloxone (Primary)
- Indications Substance-related disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Clear Scientific
Most Recent Events
- 05 May 2026 According to Clear Scientific media release, Phase 2 trials for Fentanyl are expected to begin in June 2026.
- 12 Mar 2026 New trial record